CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
B7-H3 嵌合抗原受体修饰 T 细胞显示出靶向治疗急性髓系白血病的潜力
英文原题：B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia.
查看英文原题
B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
B7-H3-CAR-T 细胞可能成为 AML 靶向治疗的一种新型治疗手段。
中文摘要
背景与目的
嵌合抗原受体（CAR）T细胞疗法是一种新型免疫疗法，但用于急性髓系白血病（AML）仍有局限。B7-H3表达于多种恶性肿瘤，包括部分AML细胞；但其在正常组织中表达较低，因此是AML靶向治疗的理想靶点。
材料与方法
我们首先构建可靶向B7-H3的CAR，随后在体外制备B7-H3 CAR-T 细胞，分别与6种B7-H3表达水平不同的AML细胞系共培养。通过流式细胞术检测细胞毒性和细胞因子。体内建立B-NSG小鼠AML模型，研究B7-H3 CAR-T 细胞对AML细胞的毒性。
结果
体外功能实验显示，B7-H3 CAR-T 细胞可杀伤B7-H3阳性AML肿瘤细胞，并能有效清除表达B7-H3的AML细胞系；细胞因子结果与此一致。体内实验显示，与对照相比，B7-H3 CAR-T 细胞显著抑制AML小鼠模型的肿瘤细胞生长并延长小鼠生存期。
结论
B7-H3 CAR-T 细胞有望成为AML靶向治疗的一种新方法。
展开英文摘要原文
MATERIALS AND METHODS
First, we constructed B7-H3 CAR that can target B7-H3, and then constructed B7-H3-CAR-T cells in vitro, which were co-incubated with six AML cell lines expressing different levels of B7-H3, respectively. The toxicity and cytokines were detected by flow cytometry. In vivo, AML model was established in B-NSG mice to study the toxicity of B7-H3-CAR T on AML cells.
RESULTS
In vitro functional tests showed that B7-H3-CAR-T cells were cytotoxic to B7-H3-positive AML tumor cells and had good scavenging effect on B7-H3-expressing AML cell lines, and the cytokine results were consistent. In vivo, B7-H3-CAR-T cells significantly inhibited tumor cell growth in a mouse model of AML, prolonging mouse survival compared with controls.
CONCLUSION
B7-H3-CAR-T cells may serve as a novel therapeutic method for the targeted treatment of AML.
论文信息
- 作者
- Fan S、Wang T、You F、Zhang T、Li Y、Ji C、Han Z、Sheng B
- 第一作者单位
- The Cyrus Tang Hematology Center, Soochow University, Suzhou, 215123, Jiangsu, China.China
- 通讯作者单位
- The Cyrus Tang Hematology Center, Soochow University, Suzhou, 215123, Jiangsu, China. yanglin@suda.edu.cn.China
- 期刊
- European journal of medical research2023 Mar 20
- 原文标识
- PubMed 36941687 · DOI 10.1186/s40001-023-01049-y
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →